EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of immune checkpoint inhibition on ovarian reserve

Elizabeth I Buchbinder iD, Zihe Song, Justine V Cohen, Sandra J Lee, Kimberly K Smith, Michael Manos, Ahmad Tarhini, Michael Dougan

The Oncologist · 05.02.2026 · 31 (3)

DOI: 10.1093/oncolo/oyag048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 28.02.2026. Verfasst von Elizabeth I Buchbinder und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Ovarian Reserve, Immune Checkpoint Inhibitors, Melanoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibition (ICI) has become a mainstay of therapy for various types of malignancy and is being used earlier in the course of therapy. In addition, there are many young women diagnosed with cancers for whom ICI is the standard of care. However, the impact of ICI on fertility is unknown and hard to assess. To evaluate this, we performed an analysis of hormones associated with ovarian reserve in young women with melanoma treated with ipilimumab. Our study showed a reduction in anti-Mullerian hormone, a marker of ovarian reserve, in patients with melanoma treated with either ICI or targeted therapy. These results support the need for further work in this area to better understand the impact these therapies have on fertility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian ReserveImmune Checkpoint InhibitorsMelanomaHumansFemaleAdultIpilimumabAnti-Mullerian Hormone

Stichwörter der Autor:innen

immune checkpoint inhibitionmelanomaovarian reserve

Substanzen

Immune Checkpoint InhibitorsIpilimumabAnti-Mullerian Hormone

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Obstetrics/Gynecology, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Department of Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Department of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.

ORCID-Profile: Elizabeth I Buchbinder

Zitieren

APA

Buchbinder, E. I., Song, Z., Cohen, J. V., Lee, S. J., Smith, K. K., Manos, M., Tarhini, A., & Dougan, M. (2026). Impact of immune checkpoint inhibition on ovarian reserve. The Oncologist, 31(3). https://doi.org/10.1093/oncolo/oyag048

Vancouver

Buchbinder EI, Song Z, Cohen JV, Lee SJ, Smith KK, Manos M, et al. Impact of immune checkpoint inhibition on ovarian reserve. The Oncologist. 2026;31(3). doi:10.1093/oncolo/oyag048

BibTeX
@article{Buchbinder2026,
  author = {Buchbinder, Elizabeth I and Song, Zihe and Cohen, Justine V and Lee, Sandra J and Smith, Kimberly K and Manos, Michael and Tarhini, Ahmad and Dougan, Michael},
  title = {Impact of immune checkpoint inhibition on ovarian reserve},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1093/oncolo/oyag048}
}
Kostenlos starten →